Cargando…

Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NM...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboulenein-Djamshidian, Fahmy, Höftberger, Romana, Waters, Patrick, Krampla, Wolfgang, Lassmann, Hans, Budka, Herbert, Vincent, Angela, Kristoferitsch, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Neuropathologists 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327561/
https://www.ncbi.nlm.nih.gov/pubmed/25668569
http://dx.doi.org/10.1097/NEN.0000000000000173
_version_ 1782357108971274240
author Aboulenein-Djamshidian, Fahmy
Höftberger, Romana
Waters, Patrick
Krampla, Wolfgang
Lassmann, Hans
Budka, Herbert
Vincent, Angela
Kristoferitsch, Wolfgang
author_facet Aboulenein-Djamshidian, Fahmy
Höftberger, Romana
Waters, Patrick
Krampla, Wolfgang
Lassmann, Hans
Budka, Herbert
Vincent, Angela
Kristoferitsch, Wolfgang
author_sort Aboulenein-Djamshidian, Fahmy
collection PubMed
description Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NMO. However, in vivo evidence combining the results of AQP4 antibody serum levels and brain pathology is lacking. We report a patient with NMO whose AQP4 antibody levels decreased simultaneously with clinical deterioration caused by the development of a tumor-like brain lesion. In the seminecrotic biopsied brain lesion, there was activated complement complex, whereas only very scattered immunoreactivity to AQP4 protein was detectable. The decrease in serum AQP4 antibody levels and the loss of AQP4 in the tumor-like lesion could represent a “serum antibody–consuming effect” during lesion formation.
format Online
Article
Text
id pubmed-4327561
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Association of Neuropathologists
record_format MEDLINE/PubMed
spelling pubmed-43275612015-03-05 Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? Aboulenein-Djamshidian, Fahmy Höftberger, Romana Waters, Patrick Krampla, Wolfgang Lassmann, Hans Budka, Herbert Vincent, Angela Kristoferitsch, Wolfgang J Neuropathol Exp Neurol Brief Report Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NMO. However, in vivo evidence combining the results of AQP4 antibody serum levels and brain pathology is lacking. We report a patient with NMO whose AQP4 antibody levels decreased simultaneously with clinical deterioration caused by the development of a tumor-like brain lesion. In the seminecrotic biopsied brain lesion, there was activated complement complex, whereas only very scattered immunoreactivity to AQP4 protein was detectable. The decrease in serum AQP4 antibody levels and the loss of AQP4 in the tumor-like lesion could represent a “serum antibody–consuming effect” during lesion formation. American Association of Neuropathologists 2015-03 2015-02-13 /pmc/articles/PMC4327561/ /pubmed/25668569 http://dx.doi.org/10.1097/NEN.0000000000000173 Text en Copyright © 2015 by the American Association of Neuropathologists, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Brief Report
Aboulenein-Djamshidian, Fahmy
Höftberger, Romana
Waters, Patrick
Krampla, Wolfgang
Lassmann, Hans
Budka, Herbert
Vincent, Angela
Kristoferitsch, Wolfgang
Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title_full Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title_fullStr Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title_full_unstemmed Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title_short Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
title_sort reduction in serum aquaporin-4 antibody titers during development of a tumor-like brain lesion in a patient with neuromyelitis optica: a serum antibody–consuming effect?
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327561/
https://www.ncbi.nlm.nih.gov/pubmed/25668569
http://dx.doi.org/10.1097/NEN.0000000000000173
work_keys_str_mv AT abouleneindjamshidianfahmy reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT hoftbergerromana reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT waterspatrick reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT kramplawolfgang reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT lassmannhans reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT budkaherbert reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT vincentangela reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect
AT kristoferitschwolfgang reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect